Shares of Edwards Lifesciences Corp (NYSE:EW) have earned a consensus rating of “Buy” from the twenty-one ratings firms that are presently covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $141.15.
Several research analysts have commented on the company. JMP Securities lifted their price target on Edwards Lifesciences from $135.00 to $140.00 and gave the stock a “market outperform” rating in a research report on Friday, February 2nd. SunTrust Banks reaffirmed a “buy” rating and set a $150.00 price target on shares of Edwards Lifesciences in a research report on Wednesday, January 31st. Guggenheim reaffirmed a “buy” rating and set a $162.00 price target on shares of Edwards Lifesciences in a research report on Friday, February 2nd. Canaccord Genuity reaffirmed a “buy” rating and set a $137.00 price target on shares of Edwards Lifesciences in a research report on Wednesday, November 29th. Finally, JPMorgan Chase & Co. lowered Edwards Lifesciences from an “overweight” rating to a “neutral” rating in a research report on Tuesday, January 2nd.
In related news, VP Donald E. Bobo, Jr. sold 5,300 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $134.70, for a total value of $713,910.00. Following the sale, the vice president now directly owns 24,908 shares in the company, valued at $3,355,107.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director William J. Phd Link sold 12,000 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $122.24, for a total value of $1,466,880.00. Following the completion of the sale, the director now owns 24,596 shares in the company, valued at $3,006,615.04. The disclosure for this sale can be found here. In the last three months, insiders sold 184,230 shares of company stock worth $22,208,032. Corporate insiders own 2.13% of the company’s stock.
Several institutional investors have recently bought and sold shares of the stock. Spectrum Asset Management Inc. NB CA boosted its stake in shares of Edwards Lifesciences by 7.4% in the fourth quarter. Spectrum Asset Management Inc. NB CA now owns 5,795 shares of the medical research company’s stock valued at $653,000 after buying an additional 400 shares in the last quarter. LS Investment Advisors LLC boosted its stake in shares of Edwards Lifesciences by 6.0% in the fourth quarter. LS Investment Advisors LLC now owns 7,789 shares of the medical research company’s stock valued at $878,000 after buying an additional 440 shares in the last quarter. Resources Investment Advisors Inc. boosted its stake in shares of Edwards Lifesciences by 66.0% in the fourth quarter. Resources Investment Advisors Inc. now owns 1,170 shares of the medical research company’s stock valued at $132,000 after buying an additional 465 shares in the last quarter. Pacer Advisors Inc. boosted its stake in shares of Edwards Lifesciences by 10.4% in the third quarter. Pacer Advisors Inc. now owns 5,312 shares of the medical research company’s stock valued at $581,000 after buying an additional 499 shares in the last quarter. Finally, Rodgers Brothers Inc. boosted its stake in shares of Edwards Lifesciences by 1.5% in the third quarter. Rodgers Brothers Inc. now owns 34,250 shares of the medical research company’s stock valued at $3,744,000 after buying an additional 500 shares in the last quarter. Hedge funds and other institutional investors own 81.23% of the company’s stock.
Edwards Lifesciences (NYSE EW) traded up $1.97 on Friday, reaching $135.64. The company’s stock had a trading volume of 872,504 shares, compared to its average volume of 1,350,000. The firm has a market capitalization of $28,700.00, a price-to-earnings ratio of 50.24, a price-to-earnings-growth ratio of 1.97 and a beta of 0.63. Edwards Lifesciences has a 52 week low of $89.20 and a 52 week high of $138.48. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.41 and a current ratio of 1.80.
Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, February 1st. The medical research company reported $0.94 EPS for the quarter, topping the consensus estimate of $0.91 by $0.03. The company had revenue of $888.50 million for the quarter, compared to analyst estimates of $868.45 million. Edwards Lifesciences had a return on equity of 27.78% and a net margin of 18.11%. The firm’s revenue was up 15.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.75 earnings per share. sell-side analysts predict that Edwards Lifesciences will post 4.49 earnings per share for the current fiscal year.
Edwards Lifesciences declared that its board has initiated a share buyback plan on Thursday, December 7th that authorizes the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to reacquire shares of its stock through open market purchases. Shares repurchase plans are typically an indication that the company’s management believes its stock is undervalued.
ILLEGAL ACTIVITY NOTICE: “Edwards Lifesciences Corp (EW) Given Consensus Recommendation of “Buy” by Brokerages” was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://ledgergazette.com/2018/02/24/edwards-lifesciences-corp-ew-given-consensus-recommendation-of-buy-by-brokerages.html.
About Edwards Lifesciences
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.